Clinical research in NSW: its role in HIV care and prevention

Damien V. Cordery; David A. Cooper

doi:10.1071/NB10017

RESEARCH ARTICLE

Previous Next Contents Vol 21(4)

Clinical research in NSW: its role in HIV care and prevention

Damien V. Cordery ^A ^B and David A. Cooper ^A

+ Author Affiliations

- Author Affiliations

^A National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales

^B Corresponding author. Email: dcordery@nchecr.unsw.edu.au

NSW Public Health Bulletin 21(4) 93-95 https://doi.org/10.1071/NB10017
Published: 27 May 2010

Abstract

Clinical research in NSW has contributed to some important breakthroughs in the understanding of many aspects for HIV transmission, pathogenesis and treatment. Researchers in NSW have played an important role in understanding the progression of HIV disease, the development and use of antiretroviral therapies and have continued to be involved in the understanding, management and prevention of HIV infection. National and international collaboration are essential in identifying and managing the complex factors required for the current management of HIV and the potential mechanisms for the future elimination of HIV.

References

[1] National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2009. National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW, 2009. Available at: http://www.nchecr.unsw.edu.au/NCHECRweb.nsf/page/Annual+Surveillance+Reports (Cited 26 February 2010.)

[2] Cooper DA, Gold J, Maclean P, Donovan B, Finlayson R, Barnes TG, et al. Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet 1985; 325 537–40.
| Crossref | GoogleScholarGoogle Scholar | PubMed | (Cited 26 February 2010.)

[5] Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12(7): F51–8.
| Crossref | GoogleScholarGoogle Scholar | PubMed | CAS |

[6] Australian HIV Observational Database Rates of combination antiretroviral treatment change in Australia, 1997–2000. HIV Med 2002; 3(1): 28–36.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[7] Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the STEP Study): a double-blind, randomised, placebo-controlled test-of-concept trial. Lancet 2008; 372 1881–93.
| Crossref | GoogleScholarGoogle Scholar | PubMed | CAS |

[8] Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361 2209–20.
| Crossref | GoogleScholarGoogle Scholar | PubMed | CAS |